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OBJECTIVES The purpose of the study was to evaluate clinical effects, exercise performance and effect on
maximal oxygen consumption (MVO2) of transmyocardial revascularization with CO2-laser
(TMR) in patients with refractory angina pectoris.
BACKGROUND Transmyocardial laser revascularization is a new method to treat patients with refractory
angina pectoris not eligible for conventional revascularization. Few randomized studies
comparing TMR with conventional treatment have been published.
METHODS One hundred patients with refractory angina not eligible for conventional revascularization
were block-randomized in a 1:1 ratio to receive continued optimal medical treatment (MT)
or TMR in addition to MT. The patients were evaluated at baseline and at three and 12
months with end points to symptoms, exercise capacity and MVO2.
RESULTS Transmyocardial laser revascularization resulted in significant relief in angina symptoms after
three and 12 months compared to baseline. Time to chest pain during exercise increased from
baseline by 78 s after three months (p 5 NS) and 66 s (p , 0.01) after 12 months in the TMR
group, whereas total exercise time and MVO2 were unchanged. No significant changes were
observed in the MT group. Perioperative mortality was 4%. One year mortality was 12% in
the TMR group and 8% in the MT group (p 5 NS.)
CONCLUSIONS Transmyocardial laser revascularization was performed with low perioperative mortality and
caused significant symptomatic improvement, but no improvement in exercise capacity.
(J Am Coll Cardiol 2000;35:1170 –7) © 2000 by the American College of Cardiology
Despite improvements in medical therapy and conventional
revascularization techniques, some patients with angina
pectoris are left with severe symptoms refractory to medical
treatment and without any possibility of using conventional
revascularization methods because of diffuse and distal
coronary artery disease. Transmyocardial laser revasculariza-
tion (TMR) has been introduced as an alternative treatment
for these patients (1,2). TMR is performed by making
channels directly through the left ventricular wall with laser
energy release by a left anterior thoracotomy approach (3).
Observational clinical studies have shown that TMR can be
performed with low operative risk, symptomatic effect in
most patients, and improved quality of life (4-6). However,
few randomized studies have been published (7-10), and
high crossover rates was reported in two studies (8,9).
The mechanisms by which TMR acts are still unclear.
The initial theory that channels remain open and perfuse
the myocardium from the left ventricular cavity has little
support in animal (11,12) and autopsy studies (13). Animal
studies have shown that TMR can reduce infarct size,
preserve contractile function (14), stimulate angiogenesis
(15) and denervate the myocardium (16). There are con-
flicting results concerning the effect on myocardial perfusion
from clinical studies (7,8,10,17). The aims of the present
study were to evaluate clinical effects of TMR superimposed
on optimal medical treatment in a randomized trial and the
potential influence on exercise electrocardiogram (ECG)
and maximal oxygen consumption (MVO2).
METHODS
Study design. The investigation was designed as an open,
prospective, single center study. Following screening, ad-
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justment of medication and a baseline evaluation, 100
eligible patients were randomized 1:1 using block-
randomization into two comparable groups to achieve either
continued optimal medical treatment alone (MT group), or
optimal medical treatment in combination with transmyo-
cardial revascularization with CO2-laser (TMR group).
Included were patients who were suffering from angina
pectoris New York Heart Association (NYHA) Functional
Class III or IV despite optimal medical treatment, were not
candidates for percutaneous transluminal coronary angio-
plasty or coronary artery bypass grafting (CABG) because of
peripheral obstructions in the coronary arteries, and were
willing to participate in a randomized study. Exclusion
criteria were age .75 years, left ventricular ejection fraction
(LVEF) , 30%, non-demonstrated reversible ischemia,
overt heart failure, inability to undergo study tests and
conditions precluding thoracic surgery. Follow-up evalua-
tions were done after three and 12 months. The scientific
protocol was approved by The Regional Ethics Committee.
Selection of patients. Between November 1995 and Jan-
uary 1998, 226 patients referred from eight hospitals in
Norway were evaluated for participation in the study (total
population of Norway 5 4.3 million). All patients had an
earlier angiogram and had been refused for CABG or
coronary angioplasty for technical reasons. The patients and
angiograms underwent a screening for the study. For opti-
mal evaluation, a new angiogram was required in 36
patients. Angina symptoms were classified according to
NYHA. Angina classifications were done unblinded by one
investigator after standardized interviews about symptoms
related to graded activities. Reversible ischemia was assessed
by exercise ECG, dobutamine stress-echo and technetium
99m (99mTc)–tetrofosmin myocardial perfusion scan
(SPECT), as at least one of these methods should show
reversible ischemia. LVEF was assessed by technetium 99m
(99mTc) multiple-gated acquisition radionuclide ventricu-
lography (MUGA). After re-evaluation, 103 patients were
eligible for inclusion (Table 1), but three died before
randomization was performed. Of those not randomized, 38
patients (17%) were offered conventional revascularization,
one in combination with aortic valve replacement. The
remaining 85 patients were excluded because of mild symp-
toms, non-demonstrated reversible ischemia, severely de-
pressed LVEF, generally reduced health condition or refusal
to participate in a randomized study. After inclusion, each
patient received an allocation number. Randomization was
then performed by opening consecutively numbered sealed
envelopes with allocation numbers and treatment inside.
One patient initially withdrew from the operation, but later
changed his mind and was operated on three months after
randomization; he has been followed up as patient who has
received the operation. All other patients were operated on
within two weeks after randomization. Evaluation, random-
ization and follow-up were done at The National Hospital.
Exercise protocol and maximal oxygen consumption
analysis. The test was performed on an electrically-braked
cycle ergometer (Ergo-metrics 900; E. Jaeger, GmbH
CoKG, Wurzenburg, Germany). The patients had ab-
stained from medication, food, coffee and nicotinic con-
sumption for 12 h prior to the test. Pedaling rate was kept
at approximately 60 rotations/min with initial workload at
10 W, which increased by 10 W/min until the end of the
test (defined as inability to continue because of chest pain,
dyspnea or exhaustion, or a halt to the test because of blood
pressure drop or arrhythmia). Maximal oxygen consumption
was measured continuously by an open-circuit technique
(Eos/Sprint; E. Jaeger, GmbH CoKG, Wurzenburg, Ger-
many). Heart rate was recorded continuously by electrocar-
diography (Siemens Megacart; Siemens-Elema AB, Swe-
den) and a 12-channel ECG was printed out every 30 s.
Blood pressure was measured non-invasively every minute
using an automatic microphone transducer blood pressure
recorder (Ergo-line; E. Jaeger, GmbH CoKG, Wurzen-
burg, Germany). Time until onset of chest pain, one
millimeter of ST segment depression and termination of
cycling were noted. Accumulated work (J 5 W 3 s) and
double product (product of systolic blood pressure and heart
rate/min) were calculated at maximal workload.
Predefined primary end points were time to one millime-
ter of ST segment depression and MVO2. Secondary end
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CCS 5 Canadian Cardiovascular Society
ECG 5 electrocardiogram
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
MT 5 medical treatment
MVO2 5 maximal oxygen consumption
NYHA 5 New York Heart Association
TMR 5 transmyocardial laser revascularization
Table 1. Selection of Patients
Result of Second Evaluation
n
(n 5 226)
Accepted for PTCA 24
Accepted for CABG 14
Excluded for other reasons
Angina , class 3 21
Reversible ischemia not demonstrated 13
LVEF ,30% or clinical overt heart failure 21
Generally reduced health condition 20
Refused participation in study 10
Accepted for study 103
Died before randomization 3
Randomized 1:1 100
CABG 5 coronary artery bypass grafting; LVEF 5 left ventricular ejection fraction;
PTCA 5 percutaneous transluminal coronary angioplasty.
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points were time to chest pain, total exercise time and
accumulated work.
Surgical procedure. All TMR operations were performed
by the same surgeon at The Feiring Heart Clinic. Surgery
was performed under combined general and thoracic epi-
dural anesthesia without cardiopulmonary bypass. A single
lumen tube was used and both lungs were inflated using an
air–oxygen mixture free from nitrous oxide. Through a left
anterior thoracotomy laser treatment was performed on the
beating heart with an 800-W CO2-laser (The Heart Laser;
PLC Medical Systems, Inc., Milford, Massachusetts,
USA). The pulses were synchronized with R-wave in the
ECG. The energy varied from 30 to 50 J, corresponding to
a pulse duration of 30 to 50 ms. About one channel/cm2 of
presumed ischemic and viable myocardium was made.
Channel formation was confirmed and left ventricular
function and possible laser-induced injuries to the submitral
apparatus were assessed through a 5 MHz multiplanar
ultrasound transesophageal probe (VingMed, Horten, Nor-
way). Thoracic epidural analgesia was continued until the
second postoperative day. Epicardial pacemaker electrodes,
pericardial drainage and IV nitroglycerin were used as usual.
Perioperative myocardial infarction (MI) was diagnosed by
new Q-waves in the ECG, CK-MB isoenzyme values .
50 mg/l, serum gluatamic oxaloacetic transaminase
(SGOT) . 100 U/l and a SGOT/serum glutamic pyruvic
transaminase (SGPT) ratio . 2:1 within 30 days after
surgery. Perioperative left ventricular dysfunction function
was clinically diagnosed (inclusive of chest X-ray) when
treatment with diuretics, inotropic agents or intra-aortic
balloon pump was required. Acute renal failure was defined
as at least a two-fold increase in serum creatinine.
Statistics. Results are given as mean 6 standard deviation
(SD) or frequency (%). The evaluation of efficacy of TMR
was done by estimating the relative changes (RC) in the
outcome variables between baseline (OBL) and follow-up
(OFU) [RC 5 (OBL 2 OFU / OBL) 3 100] for each patient
at three and 12 months. Comparisons of baseline values and
relative changes between the two groups were done using
the Student’s t-test and the Mann-Whitney non-parametric
test. The power was estimated on the two surrogate end
points, MVO2 and time to one millimeter of ST segment
depression. We considered a relative improvement of 20%
in MVO2 (an absolute improvement of 3 ml/kg/min com-
pared to baseline for the TMR group versus no improve-
ment in the MT group) and 24% in time to one millimeter
of ST segment depression (absolute improvement of 100 s
in the TMR group compared to baseline versus no improve-
ment in the MT group) as clinically important. With 50
patients in each group and a type 1 error of 5%, the
estimated power was 95% for relative change in MVO2 and
the power was 87% for relative change in time to one
millimeter of ST segment depression. Significance level was
defined as p , 0.05 (18). Analysis was performed in SPSS
for Windows, version 7.5.2.
RESULTS
Need for TMR
Patients came from all parts of Norway, but the majority
came from health region 2 with a population of 1.6 million
people. Most patients with severe angina who were not
candidates for conventional revascularization from this re-
gion were probably evaluated for inclusion in the random-
ized TMR protocol. Over the course of 27 months, 76
patients were accepted for the study from this region. Thus,
according to our criteria, a request for isolated TMR of
about 21 patients/million people/yr can be assumed. If we
include patients who refused participation in the study, the
figure would be 24 patients/million people/yr.
Baseline Characteristics
Except that the double product at maximal exercise was
higher in the TMR group than in the MT group at baseline
(p , 0.05), there were no significant differences between the
treatment groups (Table 2). Twenty-eight patients were
classified to NYHA functional class IV and 72 to functional
class III. No patient was unstable with increased symptoms
during the week prior to the beginning of the study. Mean
age for the whole group was 62.5 years (SD 3.2), and 14%
were women. The severity of the disease is underlined by the
risk profiles, concomitant diseases and number with earlier
myocardial infarction and revascularization. Mean LVEF
was 49%. The groups did not differ significantly with regard
to the extent of reversible ischemia or fixed defects as
assessed by the various methods (Table 3). Ninety-five
percent of the patients were treated with beta blocker
therapy and the majority received long acting nitrates and
Ca channel blockers as well (Table 4).
Surgical Data and Perioperative Results
An average of 48 6 7 channels were made. During surgery
one patient was found to have a graftable left anterior
descending coronary artery (LAD) not detected by angiog-
raphy. In addition to TMR, this patient received a left
internal mammary artery graft to the LAD without cardio-
pulmonary bypass, and was therefore excluded from
follow-up analyses. Four patients suffered perioperative MI.
Two patients (4%) died after 4 and 14 days, respectively,
from left ventricular failure in spite of inotropic medication,
intra-aortic balloon pump and respiratory support. Autop-
sies showed an inferior and septal infarction in the first
patient and an inferior infarction in the second patient, and
no patent channels were observed. These patients were in
preoperative functional class IV, with unprotected three-
vessel disease. LVEF was 57% and 30%, respectively. Two
additional patients had MI: one was treated for 44 days in
the intensive care unit with respiratory support and was
discharged for home care after 56 days, and the other had an
uncomplicated anterior MI and was discharged after 11
days. Seventeen patients (35%) were treated for periopera-
tive heart failure. Four patients had pulmonary infections,
1172 Aaberge et al. JACC Vol. 35, No. 5, 2000
Transmyocardial Laser Revascularization April 2000:1170–7
and two of these needed temporary respiratory support.
Mean hospital stay was 11.1 6 8.6 days with a median of
8.0 (7–56), and mean intensive care unit stay was 2.9 6 6.2
days with a median of 2.0 (1–44).
Clinical Result at Follow-up
Mortality and morbidity. Follow-up of patients after three
and 12 months was complete. However, one patient in each
group did not perform the exercise tests after 12 months:
one because of a cerebral hemorrhage and inability to
perform tests and one for personal reasons. They were
interviewed by telephone about symptoms, but otherwise
excluded from result analysis after 12 months. In addition to
the two (4%) early postoperative deaths, four patients in
each group died within one year of the randomization date.
In the TMR group one patient died from cancer, one from
intracerebral hemorrhage and two died suddenly. In the MT
group one death was caused by septicemia, one by acute MI,
one by clinical heart failure and one patient died suddenly.
There were no significant differences in hospitalizations during
the first year. In the TMR group there were 40 hospitaliza-
tions, including 17 from unstable angina and 1 from acute MI.
In the MT group there were 45 hospitalizations, including 19
from unstable angina and 1 from acute MI.
Symptomatic effects. In the TMR group, 63% experienced
an improvement of one or more functional classes after three
months, and 29% experienced an improvement of two or
more classes (Table 5). After 12 months, 71% had improved
by one or more functional classes, and 39% had improved by
two or more classes. Mean functional class was 3.3 at
baseline, 2.3 at three months and 2.0 at 12 months. In the
MT group, there were no significant changes in symptoms.
Details are shown in Figures 1 and 2.
Table 2. Patient Characteristics at Baseline
Characteristic
MT Group
(n 5 50)
TMR Group
(n 5 50)
Age (yrs, mean 6 SD) median (range) 64 6 8.1 66 (41 2 75) 61 6 8.5 62 (44 2 74)
Women (n) 6 8
Diabetes mellitus (n) 14 11
Treatment for hypertension (n) 14 14
Treatment for hypercholesterolemia (n) 41 38
Current smokers (n) 16 12
Peripheral arteriosclerosis (n) 18 15
Cerebrovascular disease (n) 7 4
Body mass index (kg/m2 6 SD) 26.7 6 3.5 26.4 6 2.8
Years since diagnosis of CHD (6 SD) 13.2 6 6.7 14.1 6 7.4
Two-vessel disease (n) 3 6
Three-vessel disease (n) 47 44
Unprotected three-vessel disease (n) 10 6
Left main stenosis (n) 16 12
Patients with previous MI (n) 35 35
Anterior MI (n) 8 9
Inferior MI (n) 6 7
Anterior and inferior MI (n) 4 1
Non-Q MI (n) 27 23
Previous revascularizations (n) 46 45
Previous CABG (n) 45 40
Previous repeat CABG (n) 12 5
Previous PTCA (n) 18 19
LVEF (MUGA, %) 49.6 6 11.9 48.9 6 11.9
NYHA class III (n) 38 33
IV (n) 12 17
CABG 5 coronary artery bypass graft; Cerebrovascular disease 5 history of cerebrovascular episodes; CHD 5 coronary heart
disease; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; MT 5 medical treatment alone; MUGA 5
multiple gated isotope ventriculography; NYHA 5 New York Heart Association; peripheral arteriosclerosis 5 symptoms of
peripheral arteriosclerosis; PTCA 5 percutaneous transluminal coronary angioplasty; SD 5 standard deviation; TMR 5
transmyocardial revascularization with laser; unprotected three vessel disease 5 three vessel disease without options for CABG
or PTCA and without functioning bypass.
No statistically significant differences between the groups.
Table 3. Percent of Patients with Positive Tests for Ischemia
before Randomization
Test TMR Group % MT Group %
Exercise ECG 82 70
SPECT 90 90
DSE 96 96
DSE 5 dobutamine stress echocardiography; ECG 5 electrocardiogram; SPECT 5
technetium 99m (99mTc)-tetrofosmin myocardial perfusion scan.
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Exercise tests. (Table 5) Time to chest pain during the
bicycle stress test increased in the TMR group by 78 6
118 s and 66 6 104 s compared to baseline values after three
and 12 months, respectively. Comparing the relative
changes in the two groups, this was significant after 12
months (p , 0.01), but not after three months. Angina was
reported as limiting exercise factor in fewer patients in the
TMR group after three (n 5 28) and 12 months (n 5 26)
compared to baseline (n 5 44). This was statistically
significant compared to baseline values and to the relative
change in the MT group (p , 0.01). There were no
clinically or statistically significant differences between the
relative changes in outcome values between the groups for
time to one millimeter of ST segment depression, double
product, total exercise time or MVO2.
Medical treatment. An increased use of angiotensin-
converting enzyme (ACE) inhibitors and diuretics and a
reduced use of aspirin was observed in the TMR group
during follow-up. The changes were statistically not signif-
icant (p .0.08). Otherwise, only minor changes occurred in
medications (Table 4).
DISCUSSION
Symptoms. The main finding in the present study was a
significant symptomatic improvement after TMR in many
patients lasting for at least one year. An improvement of two
or more functional classes was experienced by 29% and 39%
of the patients in the TMR group after three and 12
months, respectively. This is comparable with the reports
from Schofield et al. (7), but somewhat lower than reported
in other studies (5,8,10). In our study, symptoms were
classified using NYHA classification, which influences com-
parison to other studies using CCS classification. Patients in
CCS class 1 are allowed to have light symptoms, which is
not the case in the NYHA classification. Consequently,
more patients in CCS class III than in NYHA class III at
baseline are able to improve by two functional classes. An
improvement of one functional class may be considered as
clinically unimportant. However, such improvement was
reported by our patients as an important relief from symp-
toms. In the MT group no clinically important or statisti-
cally significant change was observed.
Placebo effects are expected to contribute substantially to
symptom relief when there are high expectations for the
treatment. In an open trial, even if randomized, doctor and
patient bias must be taken into consideration. Burkhoff et al.
(10) showed differences in angina score as given by an
investigator and an independent observer, while Frazier et
al. (8) did not find significant differences in scoring between
observers. Symptoms were classified after a standardized
activity-related interview in our study. Unblinded assess-
ment may, however, represent a weakness. One would
expect placebo effects to diminish over time. It has been
argued that denervation may explain early symptom relief
(16) and neoangiogenesis late improvement (15) after
TMR. There are variable reports on the development of late
symptoms after TMR (5–7). The improvement in symp-
toms from three to 12 months in our study was statistically
not significant and may be explained by spontaneous vari-
ations in the disease. In our trial we used two surrogate end
points (SEP). Usually, this kind of trial is designed to
determine whether intervention is biologically active and
whether to perform further large clinical trials with MI and
cardiac-related mortality as clinically important end points.
Our trial with SEP is equivalent to animal models, and must
be used with great caution in making clinical decisions (19).
Exercise tests. At follow-up, time to chest pain during
exercise increased significantly and fewer patients were
limited by chest pain in the TMR group, while no signifi-
cant change was seen in the MT group. This is in accor-
dance with results from other studies (4,6,7,10,17). In
contrast to reports from two recently published studies with
Table 4. Drug Treatment at Baseline and at Follow-up
MT Group TMR Group
Baseline
n 5 50
%
3 months
n 5 48
%
12 months
n 5 46
%
Baseline
n 5 49
%
3 months
n 5 46
%
12 months
n 5 43
%
Beta blockers 92 94 93 98 96 95
Ca antagonists 66 65 63 62 52 52
LA nitrates 88 94 93 90 87 90
Aspirin 80 79 76 82 74 69
Warfarin 20 21 22 26 26 26
ACE inhibitors 30 31 28 24 33 36
Statins 86 83 83 82 83 79
Diuretics 24 23 24 26 30 40
Insulin 8 8 7 10 11 12
Oral antidiabetics 10 10 11 2 0 0
ACE 5 angiotensin-converting enzyme; LA nitrates 5 long-acting nitrates; MT 5 medical treatment alone; TMR 5
transmyocardial revascularization with laser.
No statistically significant difference between the groups.
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Holmium laser (9,10), exercise capacity was not improved in
our study. Thirty-eight percent of the patients in the TMR
group were limited by symptoms other than chest pain
during follow-up (mainly dyspnea), as described by others
(7,17). Maximal oxygen consumption did not change during
follow-up in either group, and such a change in MVO2 has
not been reported in comparable studies. The deconditioned
condition of the study patients is reflected by the low
MVO2, with many in the range where heart failure patients
may be evaluated for heart transplantation (20). Donovan et
al. (21) reported reduced ischemic wall motion abnormali-
ties after TMR. It may be that exercise capacity and MVO2
are not sensitive enough to detect small functional improve-
ments in deconditioned patients. Time to one millimeter of
ST segment depression increased only slightly in the TMR
group after 12 months (p 5 NS), and was considered
clinically unimportant.
Follow-up was complete and crossover was not allowed.
This will make for more reliable results in comparison with
Figure 1. Angina symptoms in the transmyocardial revasculariza-
tion group. Circles with numbers indicate number of patients.
Arrows with numbers indicate how many and how patients have
changes in symptoms during follow-up.
Figure 2. Angina symptoms in the medical treatment group.
Symbols are as in Figure 1.
Table 5. Clinical Results of TMR vs. Medical Treatment
Baseline 3 Months 12 Months
TMR
(n 5 49)
MT
(n 5 50)
TMR
(n 5 46)
MT
(n 5 48)
TMR
(n 5 43)
MT
(n 5 46)
Angina pectoris (mean
NYHA class)
3.3 3.2 2.3* 3.1 2.0* 3.1
Improved $1 functional
class (n)
31 (63%)* 7 (14%) 35 (71%)* 11 (22%)
Improved $2 functional
classes (n)
14 (29%)* 0 19 (39%)* 0
MVO2 (ml/kg/min) 14.1 6 3.9 14.9 6 3.6 13.8 6 3.9 14.8 6 3.7 14.6 6 3.5 14.5 6 4.3
Total exercise time (s) 542 6 157 570 6 163 538 6 148 570 6 176 550 6 152 560 6 184
Maximum accumulated
work (3 103 J)
28.9 6 14.6 32.1 6 18.6 28.7 6 14.3 32.8 6 23.1 29.4 6 14.8 31.7 6 21.1
Double product at peak
stress (3 103)
27.6 6 19.5 20.6 6 8.9† 23.0 6 12.4 18.0 6 5.4 21.8 6 7.3 18.9 6 6.0
Time to chest pain (s) 409 6 122 437 6 155 487 6 152 453 6 156 475 6 150* 434 6 166
Change in time to chest
pain (s)
78 6 119 16 6 113 66 6 104* 23 6 97
Chest pain as limiting
factor (n)
44 (90%) 48 (96%) 28 (61%)* 42 (88%) 26 (62%)* 34 (76%)
Time to 1 mm ST segment
depression (s)
419 6 178 455 6 204 430 6 165 466 6 212 457 6 152 444 6 191
LVEF (%) 48.9 6 11.9 49.6 6 11.9 47.0 6 13.2 52.3 6 11.5 47.4 6 14.0 51.0 6 11.8
Deaths (n) 3 (6%) 2 (4%) 6 (12%) 4 (8%)
LVEF 5 left ventricular ejection fraction measured by multiple gated radionuclide ventriculography (MUGA); MT 5 medical treatment alone group; MVO2 5 maximal oxygen
consumption; NYHA 5 New York Heart Association; TMR 5 transmyocardial revascularization with laser group.
*p , 0.01 comparing relative changes between groups; †p , 0.05 comparing baseline values between groups.
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studies with lower follow-up proportions and crossover
design. In Norway, bicycle exercise test is commonly used as
the standard. However, walking tests and treadmill tests
may be easier to perform, and thus more sensitive in
reflecting improvements in patients who have adapted to a
quiet life over many years. Secondary metabolic changes in
peripheral muscles due to reduced activity have been de-
scribed in heart failure patients (22) and may contribute to
the lack of improvement.
Medical treatment. During the planning of the study there
was no available answer to the question of whether or not
TMR could cause a reduction in myocardial ischemia. We
therefore considered it to be of potential risk for the patients
to change from symptomatic to more silent ischemia, and
reduction in anti-ischemic therapy was not intended in
either group during follow-up. The patients were informed
of the reason for not reducing medications. This could
reduce expectations and placebo effects on the one hand, but
on the other hand should not decrease the treatment effects
compared with other studies. In addition, some patients
(p 5 NS) in the TMR group stopped taking aspirin due to
side-effects, which could affect the results.
Mortality and morbidity. Postoperative mortality was low
(4%) and comparable to the results reported by Schofield et
al. (7), Hughes (23), Krabatsch (17) and Burkhoff (10), but
favorable compared to other published studies (5,6,8,24).
We believe this was due to the strict selection criteria,
especially the exclusion of patients of advanced age, LVEF
below 30% and unstable angina, which have been shown to
predict higher mortality (6,8,25). Apart from the postoper-
ative deaths there was no difference in one-year mortality
between the groups. Our study was not designed to evaluate
late mortality (. 30 days) and these data should therefore be
interpreted with caution.
A mean of 47 channels, which is higher than in other
published studies (n 5 23–37) with CO2-laser (5–8,24),
means that with 1 channel/cm2 an average of 49 cm2 of
myocardium was treated. The optimal number of channels
has not been established. We report an incidence of early
postoperative heart failure (35%) that is higher than some
studies (5–8), but comparable to what is reported by
Hughes et al. (23). It has been shown (25) that TMR can
cause left ventricular dysfunction in the early postoperative
period, and that different mechanisms may be responsible
(26,27). Whether the number of channels is an important
factor in this respect is uncertain. The criteria for diagnosing
postoperative heart failure are not clearly defined in some
other studies and may vary from center to center. Conse-
quently, the reported incidence of heart failure may differ
between studies.
Postoperative morbidity was comparable to that reported
by Hughes et al. (23). It is noteworthy, however, that only
40% of the patients had an uncomplicated postoperative
course, underscoring the seriousness of the surgical trauma.
The increased use of ACE inhibitors and diuretics (p 5 NS)
observed in the TMR group could indicate an increase in
late heart failure. However, LVEF (MUGA) decreased only
slightly and no increase in heart failure hospitalization was
observed.
In contrast to other studies, we found no differences in
hospital admissions during follow-up. This may partly be
explained by lower numbers of hospital admissions in both
groups than reported by others (5,7). Geography, reduced
hospital availability and the intensive drug treatment in our
patients may represent other explanations.
Seventeen percent of our patients judged not to be
candidates for traditional revascularization were after re-
evaluation found to be eligible for coronary angioplasty or
CABG. This is consistent with other reports and under-
scores the importance of re-evaluating patients when no
revascularization therapy seems possible. However, some
patients will be in need of supplementary therapies.
Conclusions. In the present study, TMR was shown to be
effective in relieving symptoms, whatever the mechanisms
may be. Transmyocardial revascularization with laser is
primarily a symptomatic treatment, and so far there is no
convincing evidence of either improved myocardial function
or a reduced number of ischemic events. Therefore, the term
“heart laser treatment” may be a more appropriate term than
“transmyocardial revascularization”. With proper selection
of patients, we believe these operations can be performed
reasonably safely, but the risk for perioperative mortality and
significant morbidity should not be neglected when select-
ing patients. Whether new technology using percutaneous
transarterial access (PMR) is similarly effective and reduces
patient risk should be evaluated through properly planned
studies in the future. To further evaluate placebo effects of
TMR, results from double-blind, placebo-controlled studies
with PMR are awaited.
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